160952-52-3Relevant academic research and scientific papers
Bicyclic fibrinogen antagonists
-
, (2008/06/13)
This invention relates to compounds of the formulae: wherein A1is O, S, N—R1or CHR1; A4is N—R4or CHR4; R2is a sidechain containing an acid or ester group; R1, R4and R5are substituents such as H, alkyl and aryl alkyl, and R6is a sidechain containing a nitrogen group; and pharmaceutically acceptable salts thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.
Bicyclic fibrinogen antagonists
-
, (2008/06/13)
PCT No. PCT/US95/00248 Sec. 371 Date Jul. 3, 1996 Sec. 102(e) Date Jul. 3, 1996 PCT Filed Jan. 9, 1995 PCT Pub. No. WO96/18619 PCT Pub. Date Jul. 13, 1995Certain compounds within formula (I) are inhibitors of platelet aggregation: wherein A1 is NH or CH2;
Synthesis of a 2-benzazepine analog of a potent, nonpeptide GPIIb/IIIa antagonist
Miller, William H.,Newlander, Kenneth A.,Eggleston, Drake S.,Haltiwanger, R. Curtis
, p. 373 - 376 (2007/10/02)
The preparation of the 2-benzazepine derivative 3 as an analog of the potent, nonpeplide GPIIb/IIIa antagonist 2 is reported. The synthetic route employs as key steps a Heck arylation of dimethyl itaconate and a selective cyclization to form the aryl-fuse
